US President Donald Trump has unveiled a phased tariff plan targeting imported generic medicines, announcing that they will continue entering the United States duty-free for two years from August 1 before facing a 100% tariff for one year and a 200% tariff thereafter.
The proposal is aimed at encouraging pharmaceutical companies to relocate manufacturing to the US, with Trump warning that companies failing to establish domestic production facilities within the transition period would face steep penalties. The announcement has sparked concern among major generic drug exporters, particularly India and China, which supply a significant share of medicines consumed in the US.
While the White House argues the move will strengthen domestic manufacturing and supply chain resilience, industry experts have warned that it could increase medicine costs for American patients and disrupt global pharmaceutical trade.
Trump Pushes
In a post on his social media platform, Truth Social, Trump said all imported generic medicines would remain subject to a 0% tariff for two years beginning August 1, after which a 100% tariff would apply for one year before rising to 200%. “This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” he wrote.
Trump also clarified that the policy for patented, branded and innovative medicines would remain unchanged, as previous agreements with major pharmaceutical companies continue to apply. According to the US Food and Drug Administration (FDA), generic medicines account for more than 90% of all prescriptions dispensed in the country, making any policy affecting the sector significant for both manufacturers and consumers.
The administration has maintained that boosting domestic pharmaceutical production is critical for national security and reducing dependence on overseas supply chains.
Generic Drug Industry Faces Uncertainty
The proposed tariffs are expected to have far-reaching implications for countries that supply low-cost medicines to the US, particularly India, one of the world’s largest exporters of generic drugs. Indian pharmaceutical companies account for roughly 40% of the generic medicines imported into the US, making the American market one of their most important export destinations.
While the two-year transition period offers manufacturers time to evaluate investment plans and potential production facilities in the US, analysts caution that relocating manufacturing would require substantial capital and may not be commercially viable for many firms operating on thin profit margins. Swiss generic drugmaker Sandoz, responding to Trump’s announcement, said it would continue discussions with US policymakers and supported efforts to improve affordability and access to medicines, but added that it was too early to assess the impact on its manufacturing operations or future investments.
Market reaction was immediate, with shares of several generic drugmakers in Europe and Asia declining amid concerns over higher costs and potential disruptions to global supply chains. Industry analysts have also warned that while the policy seeks to revive domestic manufacturing, the added costs of producing medicines in the US could ultimately be passed on to patients, raising healthcare expenses rather than lowering them.
The Logical Indian’s Perspective
Affordable medicines save lives, regardless of where they are manufactured. Every country has the right to strengthen its domestic industries and improve supply chain security, but such efforts should not come at the cost of making essential healthcare less accessible. Policies affecting medicines deserve careful consultation with governments, manufacturers, healthcare professionals and patient groups because their consequences extend far beyond trade balances.
At a time when global health challenges demand greater cooperation rather than fragmentation, balancing economic priorities with equitable access to life-saving medicines is more important than ever. How can governments encourage domestic manufacturing while ensuring that patients across the world continue to receive affordable medicines without interruption?
Also Read: Sonam Wangchuk Claims Govt Assured Pradhan’s Resignation Would Be Considered
